HDL re-examined
Authors:
- Daniel J. RaderDRDaniel J. Rader
- Robert A. HegeleRHRobert A. Hegele
- 1 April 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 26 (2) , 127-132
Abstract
To summarize the current evidence concerning the role of HDL-C and HDL-associated parameters in the risk for cardiovascular disease (CVD). Numerous population studies have shown that plasma levels of HDL-C are inversely associated with CVD risk; in patient care HDL-C levels are therefore widely implemented in risk estimation models. A number of antiatherogenic properties have been ascribed to the HDL particle, but the hypothesis that HDL is causally related to CVD has been seriously challenged by recent data obtained from both human genetic studies and clinical trials. The final word on HDL-C as a therapeutic target is pending, as a number of clinical endpoint trials specifically focusing on the effect(s) of HDL-C increasing agents are underway. Moreover, recent data show that HDL efflux capacity could hold independent predictive value for CVD events, which clearly highlights the potential need to focus on HDL functionality, rather than on HDL-C levels. The dogmatic concept that HDL-C levels predict future CVD events is undisputed, but the role of HDL-C as a causal factor in atherosclerosis has been challenged by a number of different types of studies. In recent years, a paradigm shift toward 'HDL functionality' is apparent. Whether or not optimizing these markers of HDL functionality actually does reduce CVD risk requires formal testing in prospective controlled studies.Keywords
This publication has 58 references indexed in Scilit:
- Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular RisksArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL CholesterolJAMA, 2011
- Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery diseaseJournal of Clinical Investigation, 2011
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisNew England Journal of Medicine, 2011
- The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Aldosterone, Sodium, and HypertensionHypertension, 2010
- Mechanism of Action of NiacinThe American Journal of Cardiology, 2008
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007